Compare Occidental Petroleum Corporation (OXY) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Occidental Petroleum Corporation vs Zimmer Biomet Holdings Inc — how do they compare? Occidental Petroleum Corporation trades at $60.8 (market cap $60.26B), while Zimmer Biomet Holdings Inc trades at $89.52 (market cap $16.95B). The key difference: Occidental Petroleum Corporation is far larger — about 3.6× Zimmer Biomet Holdings Inc's market cap, and Occidental Petroleum Corporation pays the higher dividend (1.86%). Which is the better fit depends on your goals — on Pluang, investors hold Occidental Petroleum Corporation for 92 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| OXY | ZBH | |
|---|---|---|
Market Cap | $60.26B | $16.95B |
Volume | 11,718,920 | 2,505,240 |
Sector | Energy | Health |
52-Week High | $66.24 | $103.98 |
52-Week Low | $38.92 | $79.58 |
Typical Hold Time | 92 Days | 89 Days |
Enterprise Value | $79.02B | $24.02B |
Dividend Yield | 1.86% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Occidental Petroleum (OXY) trades at $58.21, showing slight daily weakness but maintaining a bullish technical trend with strong fundamental metrics. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 EPS of $2.40 significantly exceeding the $1.83 forecast. Valuation remains attractive with a P/E of 17.78 and EV/EBITDA of 5.56, while profitability metrics show robust margins and returns.
OXY presents compelling value with analyst consensus price target of $71.40 representing 23% upside potential. The company's debt reduction progress and strong cash flow generation support dividend sustainability. Key risks include oil price volatility and execution challenges in carbon management initiatives. Wall Street sentiment remains positive with 52% buy ratings among analysts.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Occidental Petroleum Corporation
Occidental Petroleum is an independent exploration and production company with operations in the United States, Latin America, and the Middle East. At the end of 2021, the company reported net proved reserves of 3.5 billion barrels of oil equivalent. Net production averaged 1,174 thousand barrels of oil equivalent per day in 2021 at a ratio of 75% oil and natural gas liquids and 25% natural gas.
Read more on OXY →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
